# FDA 483 - Milla Pharmaceuticals, Inc. - March 12, 2026

Source: https://www.keypedia.com/records/483/milla-pharmaceuticals-inc/d2403f8b-9084-431c-86ea-9eb8aba2b7f6

> FDA 483 for Milla Pharmaceuticals, Inc. on March 12, 2026. Product: drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Milla Pharmaceuticals, Inc.
- Inspection Date: 2026-03-12
- Product Type: drugs
- Office Name: Minneapolis District Office
- Summary: An FDA inspection of Milla Pharmaceuticals, Inc. in White Bear Lake, MN, revealed a significant deficiency in their post-marketing adverse drug experience procedures. The firm failed to develop and follow written procedures for vendor qualification and auditing, specifically regarding a pharmacovigilance vendor. This indicates a lack of oversight in critical safety reporting processes.

## Related Documents

- [483 - 2026-03-12](https://www.keypedia.com/records/483/milla-pharmaceuticals-inc/2a533c01-fed5-479f-a3ad-747ed9854418)

## Related Officers

- [Investigator](https://www.keypedia.com/people/sharon-l-matson/1d2e6d91-1d00-455d-a2e6-a73b1c6b82cc)

Company: https://www.keypedia.com/companies/milla-pharmaceuticals-inc/92858f7c-2880-43c9-97db-52b7a0ef37aa

Office: https://www.keypedia.com/offices/minneapolis-district-office/c79fc8dc-f884-48fc-ba80-2947f662511d